ReviewBritish journal of cancer2001
Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
Review in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Economic burden of haematological adverse effects in cancer patients: a systematic review.Clinical drug investigation · 2007Pooled it
- Iron states and cognitive abilities in young adults: neuropsychological and neurophysiological assessment.European archives of psychiatry and clinical neuroscience · 2008Trial
- Baseline anemia and its associated factors among adult cancer patients at Northwest Amhara Regional State Referral Hospitals, Northwest Ethiopia, 2021.Frontiers in oncology · 2024Article
- Iron Deficiency Anemia Is Associated with Proprioceptive Deficit in Adult Women: a Cross-Sectional Case-Control Study.Biological trace element research · 2023Article
- Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study.Journal of personalized medicine · 2022Article
- Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis.Cancers · 2021Article
- Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Impacts of anemia and transfusion on oncologic outcomes in patients undergoing surgery for colorectal cancer.International journal of colorectal disease · 2020Article
- Iron metabolism in diabetes-induced Alzheimer's disease: a focus on insulin resistance in the brain.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2018Review
- Preoperative Anemia as a Simple Prognostic Factor in Patients with Urinary Bladder Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Article
- Management of anemia and iron deficiency in a cancer center in France.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Mouse models of anemia of cancer.PloS one · 2014Article
- The problem of anaemia in patients with colorectal cancer.ISRN hematology · 2014Article
- Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Observational
- [Heart failure and anemia].Herz · 2013Article
- Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Article
- Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Review
- Iron deficiency can cause cognitive impairment in geriatric patients.The journal of nutrition, health & aging · 2012Article
- Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaemia is a common occurrence in patients with cancer and contributes to the clinical symptomatology and reduced quality of life (QOL) seen in cancer patients. Many aspects of reduced QOL, including fatigue, are known to be associated with suboptimally low levels of haemoglobin. Even mild-to-moderate anaemia adversely affects patient-reported QOL parameters. Red blood cell transfusions are associated with many real and perceived risks, inconveniences, costs, and only temporary benefits. Recombinant human erythropoietin (rHuEPO) is an effective therapy to increase haemoglobin values in over half of anaemic cancer patients receiving concurrent chemotherapy. These increased haemoglobin values are closely correlated with improvements in QOL. Despite these objectively defined benefits, less than 50% of anaemic patients undergoing cytotoxic chemotherapy receive rHuEPO, in contrast to patients with chronic renal failure on dialysis, where anaemia is universally and aggressively treated to more optimal haemoglobin values. However, there are several barriers that may limit more widespread use of rHuEPO. These include inconvenience associated with frequent dosing; failure of a large proportion (40 to 50%) of patients to respond; relatively slow time to response; absence of reliable early indicators of response; and current lack of rigorous pharmacoeconomic data demonstrating cost-effectiveness. Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP) that is biochemically distinct from rHuEPO, and which has been proven to stimulate red blood cell production. The molecule has a 3-fold longer half-life and increased biological activity that will allow less frequent dosing, facilitating improved management of the anaemia of cancer. With this new option for therapy, further avenues of investigation should lead to renewed interest in the clinical benefits of optimal haemoglobin levels for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.